OBJECTIVES: The objective of this study was to assess the use of colistin in a country endemic for multidrug-resistant Gram-negative bacteria (MDR-GNB). METHODS: Colistin prescription patterns were evaluated in 22 Italian centers. Factors associated with use of colistin in combination with other anti-MDR-GNB agents were also assessed. RESULTS: During the study period, 221 adults receiving colistin were included in the study. Their median age was 64 years (interquartile range 52-73), and 134 were males (61%). Colistin was mostly administered intravenously (203/221, 92%), and mainly for targeted therapy (168/221, 76%). The most frequent indications for colistin therapy were bloodstream infection and lower respiratory tract infection. Intravenous colistin was administered in combination with at least another anti-MDR-GNB agent in 80% of cases (163/203). A loading dose of 9 million units of colistimethate was administered in 79% of patients, and adequate maintenance doses in 85%. In multivariable analysis, empirical therapy (odds ratio [OR] 3.25, 95% confidence intervals [CI] 1.24-8.53, p = 0.017) and targeted therapy of carbapenem-resistant Enterobacterales infections (OR 4.76, 95% CI 1.69-13.43, p = 0.003) were associated with use of colistin in combinations with other agents, while chronic renal failure (OR 0.39, 95% CI 0.17-0.88, p = 0.024) was associated with use of colistin as monotherapy. CONCLUSIONS: Colistin remains an important option for severe MDR-GNB infections when other treatments are not available. Despite inherent difficulties in optimizing its use due to peculiar PK/PD characteristics, colistin was mostly used appropriately in a country endemic for MDR-GNB.

Use of colistin in adult patients: a cross-sectional study

Matteo Rinaldi;Stefano Di Bella;Pierluigi Viale;
2020-01-01

Abstract

OBJECTIVES: The objective of this study was to assess the use of colistin in a country endemic for multidrug-resistant Gram-negative bacteria (MDR-GNB). METHODS: Colistin prescription patterns were evaluated in 22 Italian centers. Factors associated with use of colistin in combination with other anti-MDR-GNB agents were also assessed. RESULTS: During the study period, 221 adults receiving colistin were included in the study. Their median age was 64 years (interquartile range 52-73), and 134 were males (61%). Colistin was mostly administered intravenously (203/221, 92%), and mainly for targeted therapy (168/221, 76%). The most frequent indications for colistin therapy were bloodstream infection and lower respiratory tract infection. Intravenous colistin was administered in combination with at least another anti-MDR-GNB agent in 80% of cases (163/203). A loading dose of 9 million units of colistimethate was administered in 79% of patients, and adequate maintenance doses in 85%. In multivariable analysis, empirical therapy (odds ratio [OR] 3.25, 95% confidence intervals [CI] 1.24-8.53, p = 0.017) and targeted therapy of carbapenem-resistant Enterobacterales infections (OR 4.76, 95% CI 1.69-13.43, p = 0.003) were associated with use of colistin in combinations with other agents, while chronic renal failure (OR 0.39, 95% CI 0.17-0.88, p = 0.024) was associated with use of colistin as monotherapy. CONCLUSIONS: Colistin remains an important option for severe MDR-GNB infections when other treatments are not available. Despite inherent difficulties in optimizing its use due to peculiar PK/PD characteristics, colistin was mostly used appropriately in a country endemic for MDR-GNB.
2020
15-giu-2019
Pubblicato
https://www.sciencedirect.com/science/article/pii/S2213716519301535?via=ihub
File in questo prodotto:
File Dimensione Formato  
GIACOBBE JGAR 2019 Use of colistin in adult patients a cross sectional study.pdf

Open Access dal 17/06/2020

Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Creative commons
Dimensione 457.02 kB
Formato Adobe PDF
457.02 kB Adobe PDF Visualizza/Apri
1-s2.0-S2213716519301535-main.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 513.06 kB
Formato Adobe PDF
513.06 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2944871
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 30
social impact